TICKER INTELLIGENCE
NYSE/NASDAQ: PG
7
Active Bills
0
Gov't Contracts
50
Congressional Trades
Procter & Gamble is a publicly traded company in the Healthcare sector. This company operates across Healthcare and is subject to various Congressional legislative and regulatory actions. HillSignal is tracking 7 active Congressional signals mentioning Procter & Gamble, including 7 bills. The current legislative sentiment leans bearish, with regulatory or policy headwinds potentially affecting performance.
⚠ ⚠️ PRESIDENTIAL ACTION: Presidential Memorandum signed 7/30/2026: "Presidential Determination Pursuant to Section 101 of the Defense Production Act of 1950, as Amended". This DPA action will boost investment and production in domestic critical mineral recycling and processing, likely increasing stock valuations for pure-play recovery companies and defense contractors reliant on secure rare-earth magnet supplies, while potentially raising costs for import-dependent manufacturers.
⚠ ⚠️ PRESIDENTIAL ACTION: Executive Order signed 7/20/2026: "Securing America’s Defense Supply Chains and Ensuring Domestic Acquisition of Critical Materia". The order increases compliance costs for defense contractors but boosts demand for domestic and allied sources of critical materials, benefiting U.S.-based rare earth and defense suppliers while pressuring firms reliant on foreign supply chains.
⚠ Rep. Allen sold $15K-$50K in ABT on Apr 16, 2026 — 14 days before the Wildlife Health Coordination and Zoonotic Disease Prevention Act (S4451) was introduced. While the bill could affect Abbott's infectious disease testing business, a sale ahead of neutral legislation doesn't indicate foreknowledge.
⚠ System: No overlapping signals found
⚠ System: No valid trades to analyze
⚠ System: No valid trades to analyze
⚠ Rep. Letlow bought $1,001 - $15,000 in TSM on 2026-02-02 — 8 days before the Taiwan Energy Security and Anti-Embargo Act of 2026 (S2722) advanced to the Senate Legislative Calendar, a bill that could impact semiconductor supply chains.
⚠ John Boozman bought $1,001 - $15,000 in UBER on 2026-02-06, 14 days before the Modern Worker Security Act (HR1320) advanced to the Union Calendar, which could remove regulatory risk for gig economy companies.
⚠ Rep. David J. Taylor sold $1,001 - $15,000 in AAPL on 2026-02-26 — 4 days before S3956, the "Make Billionaires Pay Their Fair Share Act," was introduced, which could lead to capital reallocation.
⚠ Rep. Doggett bought $1K-$15K in PG on Feb 17, 2026 — 33 days after the Dietary Supplement Listing Act of 2026 (S.3677) was introduced, a bill increasing FDA oversight of supplements that could shift consumer demand toward established CPG brands like Procter & Gamble.
⚠ Rep. David J. Taylor bought $1,001 - $15,000 in V (Visa Inc.) on 2026-02-09 — 2 days before HR3682 ("Financial Stability Oversight Council Improvement Act of 2025") was introduced, a bill with bullish sentiment for the financial sector.
⚠ David J. Taylor bought $1,001 - $15,000 in AAPL on 2026-01-16, 6 days before HR7085, which repeals conflict mineral disclosure requirements, was placed on the Union Calendar.
⚠ Rep. Taylor bought $15,001-$50,000 in IBM on 2026-01-08, 55 days before the Weather Research and Forecasting Innovation Reauthorization Act of 2026 (S3923) was ordered to be reported favorably, a bill with bullish sentiment for the company.
⚠ Rep. Julie Johnson bought $1,001 - $15,000 in RSG on 2025-12-18, 8 days before S216 ("Save Our Seas 2.0 Amendments Act") was enacted, which could create new revenue streams for waste management.
⚠ Rep. Case sold $1,001 - $15,000 in PG on 2025-12-01 — 16 days before HR6832, which introduces new compliance costs for consumer packaged goods manufacturers, was introduced.
⚠ Rep. Julie Johnson sold $1,001 - $15,000 in ADBE on November 3, 2025 — 2 days before the AI-Related Job Impacts Clarity Act (S3108) was introduced, a bill potentially increasing compliance burdens for tech companies.
⚠ Richard Dean Dr McCormick bought $1,001 - $15,000 in BLK (BlackRock, Inc. Common Stock) on 2025-11-05, 13 days before the "ERISA Litigation Reform Act" (HR6084) was introduced, which aims to strengthen pleading standards for ERISA lawsuits.
⚠ Rep. Marjorie Taylor Greene bought $15,001 - $50,000 in PG (Procter & Gamble Company) on 2025-11-06 — 14 days BEFORE the 'Baby Bonus Act' (HR6234) was introduced, a bill that could increase disposable income for families.
⚠ Rep. Tim Moore sold $1,001 - $15,000 in PG on September 10, 2025 — 98 days before the PACK Act (HR6832) was introduced, a bill that could increase compliance costs for consumer packaged goods manufacturers like Procter & Gamble.
⚠ Representative Taylor bought $1,001 - $15,000 in Procter & Gamble Company (PG) on 2025-09-22, 43 days before HR5917, a bill to extend nondiscriminatory trade treatment to certain countries, was introduced. This bill could positively impact companies like Procter & Gamble.
⚠ Rep. Clark sold $15,001-$50,000 in PG on 2025-09-17 — 91 days before HR6832, which could introduce new compliance costs for consumer packaged goods manufacturers, was introduced.
⚠ Representative Johnson sold $1,001 - $15,000 in APD on 2025-08-14, 20 days before the 'Stop Chinese Fentanyl Act of 2025' (HR747) was introduced. This bill expands sanctions on Chinese entities involved in opioid and precursor production.
⚠ Representative David J. Taylor bought $1,001 - $15,000 in PGR (Progressive Corporation) on 2025-07-18 — 70 days before HR5608, a bill that could expand revenue opportunities for insurance companies like Progressive.
⚠ System: No suspicious timing patterns detected
⚠ Adam Smith sold $1,001 - $15,000 in UPS on 2025-08-08 — 26 days before HR747, the "Stop Chinese Fentanyl Act of 2025," which expands sanctions on Chinese entities involved in opioid and precursor production, a potentially bearish signal for global logistics.
⚠ Rep. Franklin sold $15,001-$50,000 in MSFT on 2025-06-16 — 10 days before the STOP CSAM Act of 2025 (S1829) advanced, a bill that could increase regulatory scrutiny on tech companies.
⚠ Rep. Bentz bought $1,001-$15,000 in AMGN on June 6, 2025 — 1 day after the "Treat and Reduce Obesity Act of 2025" (S1973) was introduced, a bill aiming to expand Medicare coverage for obesity treatments.
⚠ Representative Franklin bought $1,001 - $15,000 in AMGN on 2024-08-07, 245 days before the BRAIN Act (HR2767) was introduced, a bill aiming to increase research for brain tumor treatment.
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ Rob Bresnahan sold $1,001 - $15,000 in FDX on 2025-04-08 — 1 day before the "Protecting Employees and Retirees in Business Bankruptcies Act of 2025" (S1381) was introduced, a bill aiming to increase corporate liability in bankruptcies.
⚠ George Whitesides sold $100K-$250K of Home Depot (HD) on 2025-03-24, 3 days before the 'Revitalizing Downtowns and Main Streets Act' (HR2410) was introduced, which proposes an investment tax credit for converting non-residential buildings.
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ Rep. Landsman sold $15,001 - $50,000 in JPM on March 27, 2025 — 5 days before the 'Sanctioning Russia Act of 2025' (HR2548) was introduced, a bill proposing financial restrictions.
⚠ Rep. Taylor bought $1,001 - $15,000 in PG on 2025-02-10, 3 days before HR1296 ("Expanding Child Care Access Act of 2025") was introduced, a bill that could increase consumer spending on household goods.
⚠ Rep. Lloyd Doggett bought $1,001-$15,000 in Procter & Gamble Company (PG) on February 18, 2025 — 5 days after the 'Expanding Child Care Access Act of 2025' (HR1296) was introduced, which could increase consumer spending.
⚠ Representative Shreve bought $15,001 - $50,000 in AMGN on February 24, 2025 — 8 days before the EPIC Act of 2025 (S832) was introduced, which proposes to extend market exclusivity for small-molecule drugs.
⚠ System: No suspicious timing patterns detected
⚠ Rep. Randall sold $1K-$15K in AMGN (Amgen) on Jan 6, 2025 — 3 days before the Skinny Labels, Big Savings Act (S43) was introduced, a bill that creates a safe harbor for generic drug manufacturers and is bearish for branded drug makers.
⚠ System: No suspicious timing patterns detected
⚠ Rep. Doggett bought $1K-$15K in PG (Procter & Gamble) on Nov 15, 2024 — 83 days before HR1062 (Growing and Preserving Innovation in America Act of 2025) was introduced, a bill that permanently locks in higher tax deductions for US multinationals, which could benefit consumer goods companies like P&G with foreign IP.
⚠ System: No suspicious timing patterns detected
⚠ Rep. Moskowitz bought $1K-$15K in MSFT on Sep 1, 2023 — 335 days before a $150M SSA contract to Four Points Technology for AWS Connect services, which aligns with Microsoft's cloud ecosystem.
⚠ Rep. Franklin bought $50K-$100K in ACN on Aug 7, 2024 — 19 days before Deloitte & Touche LLP secured a $66.8M Department of Veterans Affairs contract for cybersecurity transformation, a sector where Accenture competes.
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
HR6370 (Baby Changing in Health Centers Act) is an early-stage, narrow procurement bill requiring baby changing tables in federally funded health centers. It authorizes no direct appropriations, has only one cosponsor, and is stuck at committee referral. Real market data shows $KMB trading at $96.82 within its 52-week range with no abnormal volume; this bill has zero material revenue impact on any publicly traded company.
HR 1296 proposes a $5,000 refundable tax credit for home-based child care providers' startup expenses, including diapers, toys, and learning materials. The bill is in early stages (referred to Ways & Means, 39 cosponsors), but if enacted, it would directly subsidize demand for PG, KMB, MAT, and HAS consumer products. Market data shows these stocks are flat to slightly down over 30 days, reflecting no current premium for this potential catalyst.
→ Reduces after-tax cost of purchasing eligible supplies by up to 100% of the first $5,000 in expenses, effectively subsidizing demand for diapers, wipes, cleaning products, and other child care consumables
HR 7050 would end the FDA's long-standing enforcement discretion over homeopathic products and require individual pre-market approval for each product. For CHD, PG, and CLX, the affected product lines represent a small fraction of total revenue. The bill is at the earliest legislative stage and faces a long path to enactment. Market data shows no pricing of this risk: CHD is up 4.02% in 30 days, PG up 1.86%, CLX down 7.02% due to unrelated factors.
→ Pre-market approval costs and timeline likely exceed economic viability for Vicks-branded homeopathic products (e.g., Vicks ZzzQuil homeopathic sleep aid variants). Products must be withdrawn from market unless approved application is filed and granted.
HR7502 proposes a federal standard prohibiting misleading recycled content claims in consumer product marketing. The bill is in early committee stage with 9 cosponsors and limited legislative momentum. For $PG, $KO, $PEP, $KMB, and $CL, the bill imposes added compliance costs with no revenue offset — structurally bearish but low probability of passage in current form.
→ Increased compliance costs for legal review, packaging redesign, supply chain documentation, and potential liability risk for non-compliant claims; no revenue offset or new market creation.
The No Tax Breaks for Outsourcing Act (S409) would eliminate tax deferral on foreign profits for U.S. multinationals, increasing effective tax rates by 5-8 percentage points. The bill is in early stages (referred to Senate Finance Committee, 19 cosponsors) and poses a 4-8% annual net income headwind for high international-exposure companies. Despite 8-30% rallies in the last 30 days across MSFT, AAPL, GOOGL, KO, PG, XOM, and CVX, this legislative risk is not currently priced into valuations.
→ P&G's foreign income (~$7-9B) subject to current U.S. taxation. Incremental annual cost: $350M-$600M.
HR1062 permanently locks in higher FDII and GILTI deductions for US multinationals, preventing a ~3.3 ppt effective tax rate increase on foreign IP income scheduled for 2026. This directly boosts after-tax net income for companies with large international revenue streams, including MSFT, AAPL, GOOGL, AMZN, NVDA, JNJ, PFE, KO, and PG. The bill is in early committee stage — structural impact is contingent on passage through the 119th Congress.
→ PG avoids the scheduled rate increases. For P&G's ~$45B in foreign revenue, annual tax savings are approximately $300M-$500M.
The PACK Act (HR6832) introduces new regulatory burdens for consumer packaged goods manufacturers by establishing strict requirements for recyclable, compostable, and reusable claims on product packaging. This bill, currently in the early stages of the legislative process, creates compliance costs for companies like Procter & Gamble, Coca-Cola, and PepsiCo. Recent market data shows mixed performance for these companies, with some experiencing gains and others declines over the past 7 and 30 days.
→ increased compliance costs for packaging claims (recyclable, compostable, reusable) and potential for deceptive claim penalties
Daily AI-analyzed alerts for Congressional activity affecting your portfolio.
Get Started →